Companies › Ascentawits Pharmaceuticals
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AST-001 | – | Phase 1 | Solid Tumor | Aug 2027 |
| AST-3424 | – | Phase 1 | Advanced Solid Tumors | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06239155 | AST-3424 | Phase 1 | Advanced Solid Tumors | Oncology | Nov 2025 |
| NCT06245330 | AST-001 | Phase 1 | Solid Tumor | Oncology | Aug 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.